Black Friday saleUp to 70% OFF
PFIZERPFIZERPFIZER

PFIZER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

Accumulating PFE from $46.00 - $47.50 This is one of the stocks I hold indefinitely for dividends. we're at the bottom of our current channel and a double bottom is forming in a major area of support. In my previous post I stated my accumulation sections are in the lower end of the channel, so this is prime real estate to enter. Momentum downwards has come to a halt and I believe we will retest the center channel line from this point. I am diversifying a portion of profits I made from the last 2 trade set ups I've posted into PFE. A fundamentally sound entity in our current market economy. I'm sure you could assume why.
NYSE:PFELong
by WatsonsView
Charts to Pay Attention To!Just surfing the charts, seeing what's going on with stocks I haven't traded in a while and seeing a lot of things that I am like "Why is no one talking about it?!". Let's start (also, these are not math based assessments, simple chart setup based assessments): 1. Pfizer, the most obvious. We have it forming a descending triangle. Whether these are bearish or bullish tends to be hit or miss but generally they signal an impending bigger move coming. Be watching to catch it! RTX 2. RTX has broken out of a demand zone and is holding. This zone has been a reflexive area as of late and historically where RTX bounces. It has an overhead gap around 91 to 92 on the hourly chart. If RTX holds this breakout of the demand zone, the next area of slight resistance is around 91. CLX 3. CLX (Aka Clorox) honestly takes the cake. This is a really convincing chart and I am planning on probably scaling into a position for a longer term hold on this on Monday. Solid fundamentals as well CLX is trading in a low it hasn't seen since around 2018, this is something both investors and traders should be watching closely! CP 4. Ah yeah, the notorious bullish bird. My personal favourite (and invented) pattern. We see that CP has broken up of the fluttering wings of my notorious bullish bird. Positive momentum with it favoring a bullish continuation into next week based on a simple probability assessment. We should be seeing it hit the 80 mark very soon and expect to see some pullback before any continuation up. But I am personally watching this myself. T 5. Poor AT&T. Regardless of your position on this company and its practices T has not seen these lows since 2009. Its extremely oversold and its likely going to rebound in a massive way and you can bet that I am going to be looking to enter on Monday. TMO 6. Company with a sick name. Does a lot of research analytics stuff. I am not overly familiar with their fundamentals, aside from solid earner and established company that has continued to deliver to investors, which is great, but so is its chart. That's it! Just wanting to draw notice to some of these more neglected stocks that not many think about. Hope you found it interesting! Trade safe everyone!
NYSE:PFE
by Steversteves
3
Pfizer's going to rocket?I didn't take a look at Pfizer for quite a while, but just recently going through the list of my favourite stocks I noticed it from the first glance. Something is going to happen... This declining volume, overlapping of price and a bit of a volume spike on 11th August, all seems to be in line. The 3rd wave formed in December 2021 and we had a correction for almost a year, now it's time to move on. Fly PFE fly! Invalidation point is 46.28, with min target of 61-65. Good luck trader!
NYSE:PFELong
by rO_Oute
4
Pfeizer peaked, now losing momentum. PFEGoals 0.56, 0.49. Invalidation at 0.89. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NYSE:PFEShort
by Rykin_Capital
PFE: Triangle break!Pfizer Short Term - We look to Sell at 50.48 (stop at 52.47) Our outlook is bearish. Broken out of the triangle formation to the downside. This is negative for sentiment and the downtrend has potential to return. Further downside is expected although we prefer to sell into rallies close to the 51.00 level. Our profit targets will be 45.49 and 42.00 Resistance: 50.00 / 54.00 / 62.00 Support: 45.00 / 40.00 / 34.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:PFEShort
by VantageMarkets
Pfizer | Fundamental Analysis | Must ReadSo far this year has not been kind to stock markets. And while many drug makers have avoided a selloff, Pfizer is not one of them. The pharmaceutical giant has performed more or less on par with the broader market to date. Fortunately, Pfizer's latest quarterly report showed some very encouraging signs. However, there are also reasons to be concerned about the future of this medical company. Let's look at one earnings-related reason why Pfizer might be a buy and one reason why it might not be. Pfizer has made a fortune over the past couple of years through its work on coronaviruses. The company continues to benefit greatly from these efforts. In Q2, the company's revenues rose 53% year over year to $27.7 billion. According to company executives, Pfizer recorded the largest quarterly sales in its history during the period, and that was primarily due to its COVID-19 product line. Sales of the coronavirus vaccine totaled $8.8 billion, up 20% from last year. Sales of the coronavirus drug Paxlovid were $8.1 billion (no year-over-year comparison here, since the drug received approval in December). These two drugs alone accounted for more than half of Pfizer's total revenue. While Pfizer's line of drugs against coronaviruses is currently unparalleled, the rest of the company's portfolio is not as impressive. The non-coronavirus drug maker's revenues grew a paltry 1% year-over-year in Q2. Pfizer's line of drugs faces a number of challenges, including adverse events related to its immunologic drug Xeljanz. Xeljanz belongs to a class of drugs known as JAK inhibitors. Last year, Pfizer published data from a post-marketing study that showed Xeljanz was associated with higher rates of cardiovascular events and cancer than TNF inhibitors, a drug category that includes AbbVie's Humira. The results of this study, combined with a regulatory decision to add a warning about these risks to the label of Xeljanz (and other JAK inhibitors), are holding back sales of the drug. In Q2, sales of Xeljanz declined 24% year over year to $430 million. Revenues for the immunosuppressant Enbrel also fell 10% year over year to $257 million, probably because of tougher competition, which also affected its sales in Q1. Pfizer has some good non-coronavirus numbers, including its drug Eliquis. In Q2, sales of that anticoagulant rose 23% year over year to $1.7 billion. But overall, the company has barely been able to increase sales outside of its line of coronavirus drugs. This could be a problem if sales of COVID-19 products fall sharply after this year. In my opinion, the market is still underestimating Pfizer. First, the company will continue to make profits from Paclovid and Comirnati. COVID-19 will not (unfortunately) suddenly disappear out of thin air after this year. Even if the demand for drugs to prevent or treat the disease declines, Paxlovid and Komirnati can continue to make significant contributions to Pfizer's top-line revenue for a long time to come. Second, while the rest of the drug line is unimpressive, pharmaceutical companies sometimes face this problem because of growing competition, patent breaks, or other factors. But drug makers generally don't have the advantage of growing sales at the rate that Pfizer does when they face such obstacles. What matters is whether the company in question can meet these challenges. Having a solid portfolio and plenty of money to devote to research and development helps - and Pfizer has both. Thanks to the company's success in the coronavirus market, its cash balance has skyrocketed. Pfizer has been active in acquisitions and plans to continue on that path. This should help bolster its already solid line of drugs, which has more than 90 clinical trials. Pfizer expects up to 15 new approvals over the next 18 months. Some of the current programs could go wrong. But the company has all the tools it needs to launch several new potential blockbuster drugs in the next five years. That's why investors should siphon off the company's stock before it rises in price.
NYSE:PFELong
by FOREXN1
10
Symmetrical Triangle/Rising Wedge.Earnings 7-28 BMO Neutral pattern until a trendline is broken. Targets over the triangle are bullish targets if triangle breaks to the upside. Targets below the structure are bearish targets if this breaks to the downside. Price has broken bottom trendline of the triangle and recovered using a prior gap as support. Doji candle on Friday/indecision. Short percent is 1.23% approximate and ratio is 2.9. Earnings can make going long or short tricky so I will wait and see what happens. Longer term I feel this is a short due to the rising wedge. You may see this chart differently than I do. No recommendation. There is an old bearish rising wedge ( LOOK LEFT) in this chart just below $40. This pattern has not been validated. This pattern is not valid until the bottom trendline is broken. If history repeats itself, this rising wedge will eventually be broken.
NYSE:PFEShort
by lauralea
1